Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection.

Beyranvand Nejad E, Ratts RB, Panagioti E, Meyer C, Oduro JD, Cicin-Sain L, Früh K, van der Burg SH, Arens R.

J Immunother Cancer. 2019 Jan 31;7(1):25. doi: 10.1186/s40425-019-0500-9.

2.

The importance of correctly timing cancer immunotherapy.

Beyranvand Nejad E, Welters MJ, Arens R, van der Burg SH.

Expert Opin Biol Ther. 2017 Jan;17(1):87-103. Epub 2016 Nov 16. Review.

PMID:
27802061
3.

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.

Beyranvand Nejad E, van der Sluis TC, van Duikeren S, Yagita H, Janssen GM, van Veelen PA, Melief CJ, van der Burg SH, Arens R.

Cancer Res. 2016 Oct 15;76(20):6017-6029. Epub 2016 Aug 28.

4.

Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.

van der Sluis TC, van Duikeren S, Huppelschoten S, Jordanova ES, Beyranvand Nejad E, Sloots A, Boon L, Smit VT, Welters MJ, Ossendorp F, van de Water B, Arens R, van der Burg SH, Melief CJ.

Clin Cancer Res. 2015 Feb 15;21(4):781-94. doi: 10.1158/1078-0432.CCR-14-2142. Epub 2014 Dec 12.

Supplemental Content

Loading ...
Support Center